GeneDx Holdings Corp - Class A risk profile
42 Elevated one input has moved against it
Measured 21 October 2026 from WGS's filed statements. Recomputed nightly.
42 (Elevated), driven by Market expectation at 77, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 77 | Stretched | Volatile | One-year price volatility — 86.0% |
| Operating pressure | 12 | Contained | Worsening | Costs outgrowing revenue — -5.9 percentage points |
| Cash conversion | 51 | Elevated | Easing | Capital spending against operating cash — 0.57x |
| Leverage and coverage | 9 | Contained | Worsening | Current ratio — 2.46x |
| Competitive position | 50 | Elevated | Stable | Operating-margin gap against peers — -6.8 percentage points |
| Concentration | 59 | Elevated | Worsening | Customer concentration — 2,050 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for GeneDx Holdings Corp - Class A